Efficacy of 3TC therapy in children with chronic hepatitis B;Skuteczność 3TC w leczeniu dzieci z przewlełym zapaleniem wa̧troby typu B

Pediatria Polska

Volumn 76, Issue 8, 2001, Pages 579-584

  Majda Stanislawska, E ^a  

^a UM   (Poland)

Author keywords

3TC; Children; Chronic hepatitis B; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIHISTAMINIC AGENT; ASPARTATE AMINOTRANSFERASE; HEPATITIS B(E) ANTIBODY; LAMIVUDINE;

ABDOMINAL PAIN; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEPATITIS B; HUMAN; LIVER BIOPSY; MALE; RASH; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 0034750489     PISSN: 00313939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Szczepienia przeciw wirusowemu zapaleniu wa̧troby typu B
2. Comparison of standard and high dosage recombinanat interferon α2b for the treatment of children with chronic hepatitis B infection
3. Retreatment with higher dose interferon alpha in children with chronic hepatitis B infection
4. Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis
5. α-Interferon therapy and peripheral neuropathy
6. Interferon-α-associated monoarthritis
7. Transient hypothyroidism in a child treated with α-interferon for chronic hepatitis B infection
8. Reversible cardiomyopathy secondary to α-interferon in an infant
9. Growth retardation as a long-term side-effect of α-interferon therapy
10. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation
11. Interferon-alpha treatment of chronic hepatitis B in childhood: A consensus advice based on experience in European children
12. Formulation and application of a numerical scoring system for assessing histological activity in symptomaticchronic active hepatitis
13. Histological classification of chronic hepatitis
14. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection
15. A preliminary trial of lamivudine for chronic hepatitis B infection
16. Role of lamivudine in the treatment of chronic hepatitis B virus infection
17. Lamivudine treatment for children with interferon refractory chronic hepatitis B
18. Lamivudine in children with human immunodeficiency vires infection: A phase I/II study
19. A dose ranging study of pharmacokinetics, safety and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B
20. One year trial of lamivudine for chronic hepatitis B
21. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine
22. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study
23. Lamivudine. A review of its therapeutic potential in chronic hepatitis B
24. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
25. Long-term therapy of chronic hepatitis B with lamivudine
26. Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B
27. Pretherapy alanine transaminase level as a determinant for hepatitis B a seroconversion during lamivudine therapy of patients with chronic hepatitis B
28. Mutation of HBV RNA-dependent DNA polymerase confers resistance in lamivudine in vivo